Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma

Interventions: Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2005-09-15

Last Posted Date: 2023-06-01

Lead Sponsor: Susanne Arnold

Target Recruit Count: 26

Registration Number: NCT00176267

Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2005-09-15

Last Posted Date: 2016-03-25

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 129

Registration Number: NCT00170664

Locations: 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Phase 2

Completed

Conditions: Neuroblastoma
Ewings Sarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling

Phase 2

Terminated

Conditions: Advanced Non-Small Cell Lung Cancer

First Posted Date: 2005-09-12

Last Posted Date: 2008-07-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 1

Registration Number: NCT00161278

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Phase 2

Completed

Conditions: Carcinoma
Non-Squamous Non-Small-Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: CDP791 10mg/kg
Drug: CDP791 20mg/kg

First Posted Date: 2005-09-09

Last Posted Date: 2022-04-12

Lead Sponsor: UCB Pharma

Target Recruit Count: 165

Registration Number: NCT00152477

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: Taxotere
Drug: Navelbine
Drug: Carboplatin

First Posted Date: 2005-09-08

Last Posted Date: 2013-04-09

Lead Sponsor: Eric Winer, MD

Target Recruit Count: 81

Registration Number: NCT00148668

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Phase 2

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-09-08

Last Posted Date: 2005-11-29

Lead Sponsor: St. John Providence Health System

Target Recruit Count: 45

Registration Number: NCT00150657

Locations: 🇺🇸
Providence Cancer Institute, Southfield, Michigan, United States

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Phase 2

Completed

Conditions: Urologic Neoplasms

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-09-08

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT00151034

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
California City of Hope National Medical Group, Duarte, California, United States

and more 8 locations